April 19, 2011 at 12:02 PM EDT
Profit Taking Weighs Down Amarin

Investors locked in profits on Amarin Corp. (Nasdaq: AMRN), whose stock price surged yesterday on upbeat results from a Phase 3 ANCHOR trial for its AMR101. Shares of the biopharmaceutical dropped $1.47 to $15.63.




Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here